Home › Venous Thromboembolism › NCT05756244
PRospective Evaluation of Peripartum Anticoagulation ManaGement for ThrOmboembolism
RecruitingObservational study
A Prospective Cohort Study Evaluating Peripartum Anticoagulation Management Among Pregnant Women With Venous Thromboembolism and Its Impact on Patient Outcomes
Who can join
Ages 18 to 60 · Women
Full eligibility criteria
Inclusion Criteria: * 18 years of age or older * Requires anticoagulation during the antepartum period of pregnancy for a VTE indication, including at least one of: 1. Objectively confirmed VTE (DVT, superficial vein thrombosis \[SVT\], PE or unusual site thrombosis) diagnosed during the current pregnancy; 2. Objectively confirmed VTE diagnosed in a prior pregnancy; 3. Objectively confirmed VTE diagnosed when not pregnant; 4. Inherited or acquired thrombophilia requiring anticoagulation. * Receiving any dose or type of LMWH during the antepartum period Exclusion Criteria: * Anticoagulation for a non-VTE indication, including prosthetic heart valves, atrial fibrillation, prevention of placenta-mediated pregnancy complications, or prevention of recurrent pregnancy loss (participants can be included with a diagnosis of antiphospholipid syndrome (APS) with or without thrombotic events) * Unable to provide or declined consent. * Home or birthing centre planned delivery.
About the study
The PREP and GO study is an international multicentre prospective cohort evaluating anticoagulation management strategies around labor and delivery and the postpartum period.
Sponsor: University of Calgary · Participants: 825 · Started: Apr 4, 2023
Contact the study team
- Jill Baxter, BSc · Phone: 403-220-7103
- Leslie Skeith, MD · Phone: 403-944-5246
Official record on ClinicalTrials.gov — NCT05756244
Locations in the U.S.
| North Carolina | Duke University Hospital, Durham |
Conditions
From ClinicalTrials.gov, data retrieved Oct 2, 2026. Each study sets its own eligibility; the study team decides who can join.